This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Surgery  • Surgical Interventions  • Surgical Oncology  • Prognosis/ Outcomes  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

The Massachusetts General Hospital Experience From 1977 to 2005

Parsia A. Vagefi, MD; Oswaldo Razo, MD; Vikram Deshpande, MD; Deborah J. McGrath, RN; Gregory Y. Lauwers, MD; Sarah P. Thayer, MD, PhD; Andrew L. Warshaw, MD; Carlos Fernández-del Castillo, MD

Arch Surg. 2007;142:347-354.

Objective  To assess changing patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms (PNENs).

Design  Retrospective review from May 21, 1977, through September 16, 2005.

Setting  Massachusetts General Hospital, a tertiary care center.

Patients  We evaluated 168 patients (51% male; mean age, 56 years) who underwent surgery for histologically confirmed PNENs.

Main Outcome Measures  Surgical outcomes, survival, and changes in presentation of PNENs in 2 time groups: 1977-1999 (77 patients) and 2000-2005 (91 patients).

Results  Ninety-eight patients (58.3%) had nonfunctioning PNENs, 86 of which were incidental. Insulinomas were the most common type of functional neoplasm (33.3%), followed by gastrinomas and glucagonomas; 12 patients (7.1%) had multiple endocrine neoplasia type 1. Of the neoplasms, 107 (63.7%) were located in the pancreatic body or tail. A pancreaticoduodenectomy was performed in 37 patients (22.0%), distal pancreatectomy was done in 88 (52.4%), and the rest had either middle segment pancreatectomy or enucleation. There were no operative deaths. We classified 76.8% of neoplasms as benign; of those classified as malignant, 25.6% had liver metastases. Of the patients, 10.1% received adjuvant therapy. Complete follow up was available in 90.5% of patients (mean, 63.3 months). Five- and 10-year actuarial survival rates were 77% and 62%, respectively. Incidentally discovered nonfunctioning neoplasms were significantly more frequent in the last 5 years (60.4% vs 40.3%; P = .007), with a trend toward smaller neoplasms (mean, 4.2 cm vs 5.6 cm; P = .19) and lesser likelihood of malignancy (21.8% vs 40.0%; P = .08).

Conclusions  We report a large single-center experience with PNENs. Increasing numbers of PNENs are being resected, largely owing to the incidental detection of nonfunctioning neoplasms. This may lead to the treatment of smaller and less malignant neoplasms.

Author Affiliations: Department of Surgery (Drs Vagefi, Razo, Thayer, Warshaw, and Fernández-del Castillo and Ms McGrath) and Department of Pathology (Drs Deshpande and Lauwers), Massachusetts General Hospital/Harvard Medical School, Boston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?